$2763 | SAVE $487 | Single User
$5525 | SAVE $975 | Site License
$8288 | SAVE $1,462 | Enterprise License

Ulcerative Colitis -Epidemiology Forecast to 2027

Ulcerative Colitis (UC) -Epidemiology Forecast to 2027
[Lowest Price Guaranteed: $2,763]

Published by Delve Insight: 14 Feb 2018 | 201698 | In Stock
Related Topics: Ulcerative Colitis

Introduction

DelveInsight's "Ulcerative Colitis (UC) - Epidemiology Forecast, 2027” report provides a comprehensive analysis of the Ulcerative Colitis (UC) epidemiology, providing the historical and forecasted data for the 7MM during the forecast period from 2016-2027.

Markets Covered

• United States

• EU5 (Germany, France, Italy, Spain, and the United Kingdom)

• Japan

Study Period: 2016-2027

Ulcerative Colitis (UC) Epidemiology

The epidemiology section covers the historical, current as well as forecasted epidemiology for Ulcerative Colitis (UC) in 7 major markets. The data is collected by understanding the disease, reviewing numerous studies conducted by countries and by exploring different surveys as well as reports. The Key opinion leaders’ views are also taken into account to provide a deep understanding of the Ulcerative Colitis (UC) outlook. It also includes the explanation of changing trends of epidemiology outlining the Ulcerative Colitis (UC) scenario.

Ulcerative Colitis (UC) Epidemiology Segmentation

The epidemiology section is further segmented according to the patient pool characteristics, such as age-specific, type-specific, sub-type specific, gender-specific etc., thus providing an in-depth and high-quality analysis. The report also covers the prevalent/Incidence cases as well as the treatable cases as per the therapies available for the Ulcerative Colitis (UC) thereby presenting the trends with detailed analysis, with the assumptions undertaken. The data is presented in the form of graphs along with tables to effectively summarize the landscape.

Report Scope

• The report covers detailed overview of Ulcerative Colitis (UC) explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns

• It provides the insight about the historical and forecasted patient pool for 7 major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan

• The Ulcerative Colitis (UC) Report assesses the disease risk and burden and highlights the unmet needs

• It also helps to recognize the growth opportunities in the 7MM with respect to the patient population

Key strengths

• 10 Year Forecast

• 7MM Coverage

• Total Cases in Ulcerative Colitis (UC)

Key assessments

• Patient Segmentation in Ulcerative Colitis (UC)

• Ulcerative Colitis (UC) Risk & Burden

• Factors driving growth in a specific Ulcerative Colitis (UC) patient population

Table of Contents
for Ulcerative Colitis (UC) -Epidemiology Forecast to 2027

  • 1. Report Introduction

    2. Ulcerative Colitis (UC) Epidemiology Overview at a Glance

    2.1. Patient Share Distribution of Ulcerative Colitis (UC) in 2017

    2.2. Patient Share Distribution of Ulcerative Colitis (UC) in 2027

    3. Disease Background and Overview: Ulcerative Colitis (UC)

    3.1. Introduction

    3.2. Symptoms

    3.3. Etiology

    3.4. Risk Factors

    3.5. Pathophysiology

    3.6. Diagnosis

    3.7. Treatment

    4. Epidemiology and Patient Population

    4.1. Key Findings

    4.2. Total Prevalent/ Incident Patient Population of Ulcerative Colitis (UC) in 7MM

    4.3. Total Prevalent/ Incident Patient Population of Ulcerative Colitis (UC) in 7MM – By Countries

    5. Epidemiology of Ulcerative Colitis (UC) by Countries

    5.1. United States

    5.1.1. Assumptions and Rationale

    5.1.2. Prevalent/Incident Cases of the Ulcerative Colitis (UC)

    5.1.3. Sub-Type Specific cases of the Ulcerative Colitis (UC) *

    5.1.4. Sex- Specific Cases of the Ulcerative Colitis (UC)*

    5.1.5. Diagnosed Cases of the Ulcerative Colitis (UC)

    5.2. EU5

    5.3. Assumptions and Rationale

    5.4. Germany

    5.4.1. Assumptions and Rationale

    5.4.2. Prevalent/Incident Cases of the Ulcerative Colitis (UC)

    5.4.3. Sub-Type Specific cases of the Ulcerative Colitis (UC)*

    5.4.4. Sex- Specific Cases of the Ulcerative Colitis (UC)*

    5.4.5. Diagnosed Cases of the Ulcerative Colitis (UC)

    5.5. France

    5.5.1. Assumptions and Rationale

    5.5.2. Prevalent/Incident Cases of the Ulcerative Colitis (UC)

    5.5.3. Sub-Type Specific cases of the Ulcerative Colitis (UC)*

    5.5.4. Sex- Specific Cases of the Ulcerative Colitis (UC)*

    5.5.5. Diagnosed Cases of the Ulcerative Colitis (UC)

    5.6. Italy

    5.6.1. Assumptions and Rationale

    5.6.2. Prevalent/Incident Cases of the Ulcerative Colitis (UC)

    5.6.3. Sub-Type Specific cases of the Ulcerative Colitis (UC)*

    5.6.4. Sex- Specific Cases of the Ulcerative Colitis (UC)*

    5.6.5. Diagnosed Cases of the Ulcerative Colitis (UC)

    5.7. Spain

    5.7.1. Assumptions and Rationale

    5.7.2. Prevalent/Incident Cases of the Ulcerative Colitis (UC)

    5.7.3. Sub-Type Specific cases of the Ulcerative Colitis (UC)*

    5.7.4. Sex- Specific Cases of the Ulcerative Colitis (UC)*

    5.7.5. Diagnosed Cases of the Ulcerative Colitis (UC)

    5.8. United Kingdom

    5.8.1. Assumptions and Rationale

    5.8.2. Prevalent/Incident Cases of the Ulcerative Colitis (UC)

    5.8.3. Sub-Type Specific cases of the Ulcerative Colitis (UC)*

    5.8.4. Sex- Specific Cases of the Ulcerative Colitis (UC)*

    5.8.5. Diagnosed Cases of the Ulcerative Colitis (UC)

    5.9. Japan

    5.9.1. Assumptions and Rationale

    5.9.2. Prevalent/Incident Cases of the Ulcerative Colitis (UC)

    5.9.3. Sub-Type Specific cases of the Ulcerative Colitis (UC)*

    5.9.4. Sex- Specific Cases of the Ulcerative Colitis (UC)*

    5.9.5. Diagnosed Cases of the Ulcerative Colitis (UC)

    6. Unmet Needs of the Ulcerative Colitis (UC)

    7. Appendix

    8. Report Methodology

    8.1. Sources

    9. DelveInsight Capabilities

    10. Disclaimer

    11. About DelveInsight

    *Indication Specific

List Of Tables
in Ulcerative Colitis -Epidemiology Forecast to 2027

Table 1: Total Prevalent/Incident Cases of the Ulcerative Colitis (UC) in 7MM

Table 2: Total Prevalent/Incident Cases of the Ulcerative Colitis (UC) in 7MM by Countries

Table 3: Prevalent/Incident Cases of the Ulcerative Colitis (UC) in United States (2016-2027)

Table 4: Sub-Type Specific cases of the Ulcerative Colitis (UC) in United States (2016-2027)*

Table 5: Sex- Specific Cases of the Ulcerative Colitis (UC) in United States (2016-2027)*

Table 6: Diagnosed Cases of the Ulcerative Colitis (UC) in United States (2016-2027)

Table 7: Prevalent/Incident Cases of the Ulcerative Colitis (UC) in Germany (2016-2027)

Table 8: Sub-Type Specific cases of the Ulcerative Colitis (UC) in Germany (2016-2027) *

Table 9: Sex- Specific Cases of the Ulcerative Colitis (UC) in Germany (2016-2027) *

Table 10: Diagnosed Cases of the Ulcerative Colitis (UC) in Germany (2016-2027)

Table 11: Prevalent/Incident Cases of the Ulcerative Colitis (UC) in France (2016-2027)

Table 12: Sub-Type Specific cases of the Ulcerative Colitis (UC) in France (2016-2027) *

Table 13: Sex- Specific Cases of the Ulcerative Colitis (UC) in France (2016-2027) *

Table 14: Diagnosed Cases of the Ulcerative Colitis (UC) in France (2016-2027)

Table 15: Prevalent/Incident Cases of the Ulcerative Colitis (UC) in Italy (2016-2027)

Table 16: Sub-Type Specific cases of the Ulcerative Colitis (UC) in Italy (2016-2027) *

Table 17: Sex- Specific Cases of the Ulcerative Colitis (UC) in Italy (2016-2027) *

Table 18: Diagnosed Cases of the Ulcerative Colitis (UC) in Italy (2016-2027)

Table 19: Prevalent/Incident Cases of the Ulcerative Colitis (UC) in Spain (2016-2027)

Table 20: Sub-Type Specific cases of the Ulcerative Colitis (UC) in Spain (2016-2027) *

Table 21: Sex- Specific Cases of the Ulcerative Colitis (UC) in Spain (2016-2027) *

Table 22: Diagnosed Cases of the Ulcerative Colitis (UC) in Spain (2016-2027)

Table 23: Prevalent/Incident Cases of the Ulcerative Colitis (UC) in UK (2016-2027)

Table 24: Sub-Type Specific cases of the Ulcerative Colitis (UC) in UK (2016-2027) *

Table 25: Sex- Specific Cases of the Ulcerative Colitis (UC) in UK (2016-2027) *

Table 26: Diagnosed Cases of the Ulcerative Colitis (UC) in UK (2016-2027)

Table 27: Prevalent/Incident Cases of the Ulcerative Colitis (UC) in Japan (2016-2027)

Table 28: Sub-Type Specific cases of the Ulcerative Colitis (UC) in Japan (2016-2027) *

Table 29: Sex- Specific Cases of the Ulcerative Colitis (UC) in Japan (2016-2027) *

Table 30: Diagnosed Cases of the Ulcerative Colitis (UC) in Japan (2016-2027)

List Of Figures, Charts and Diagrams
in Ulcerative Colitis -Epidemiology Forecast to 2027

Table 1: Total Prevalent/Incident Cases of the Ulcerative Colitis (UC) in 7MM

Table 2: Total Prevalent/Incident Cases of the Ulcerative Colitis (UC) in 7MM by Countries

Table 3: Prevalent/Incident Cases of the Ulcerative Colitis (UC) in United States (2016-2027)

Table 4: Sub-Type Specific cases of the Ulcerative Colitis (UC) in United States (2016-2027)*

Table 5: Sex- Specific Cases of the Ulcerative Colitis (UC) in United States (2016-2027)*

Table 6: Diagnosed Cases of the Ulcerative Colitis (UC) in United States (2016-2027)

Table 7: Prevalent/Incident Cases of the Ulcerative Colitis (UC) in Germany (2016-2027)

Table 8: Sub-Type Specific cases of the Ulcerative Colitis (UC) in Germany (2016-2027) *

Table 9: Sex- Specific Cases of the Ulcerative Colitis (UC) in Germany (2016-2027) *

Table 10: Diagnosed Cases of the Ulcerative Colitis (UC) in Germany (2016-2027)

Table 11: Prevalent/Incident Cases of the Ulcerative Colitis (UC) in France (2016-2027)

Table 12: Sub-Type Specific cases of the Ulcerative Colitis (UC) in France (2016-2027) *

Table 13: Sex- Specific Cases of the Ulcerative Colitis (UC) in France (2016-2027) *

Table 14: Diagnosed Cases of the Ulcerative Colitis (UC) in France (2016-2027)

Table 15: Prevalent/Incident Cases of the Ulcerative Colitis (UC) in Italy (2016-2027)

Table 16: Sub-Type Specific cases of the Ulcerative Colitis (UC) in Italy (2016-2027) *

Table 17: Sex- Specific Cases of the Ulcerative Colitis (UC) in Italy (2016-2027) *

Table 18: Diagnosed Cases of the Ulcerative Colitis (UC) in Italy (2016-2027)

Table 19: Prevalent/Incident Cases of the Ulcerative Colitis (UC) in Spain (2016-2027)

Table 20: Sub-Type Specific cases of the Ulcerative Colitis (UC) in Spain (2016-2027) *

Table 21: Sex- Specific Cases of the Ulcerative Colitis (UC) in Spain (2016-2027) *

Table 22: Diagnosed Cases of the Ulcerative Colitis (UC) in Spain (2016-2027)

Table 23: Prevalent/Incident Cases of the Ulcerative Colitis (UC) in UK (2016-2027)

Table 24: Sub-Type Specific cases of the Ulcerative Colitis (UC) in UK (2016-2027) *

Table 25: Sex- Specific Cases of the Ulcerative Colitis (UC) in UK (2016-2027) *

Table 26: Diagnosed Cases of the Ulcerative Colitis (UC) in UK (2016-2027)

Table 27: Prevalent/Incident Cases of the Ulcerative Colitis (UC) in Japan (2016-2027)

Table 28: Sub-Type Specific cases of the Ulcerative Colitis (UC) in Japan (2016-2027) *

Table 29: Sex- Specific Cases of the Ulcerative Colitis (UC) in Japan (2016-2027) *

Table 30: Diagnosed Cases of the Ulcerative Colitis (UC) in Japan (2016-2027)

Additional Details

Publisher

Delve Insight

Publisher Information

DelveInsight is a leading Business Consulting and Market Research Firm. We combine industry expertise with probing market insights in innovative ways to deliver enduring results to deliver critical information to leading decision makers.



We help our clients to find answers relevant to their business, facilitating decision-making; identify potential market opportunities, competitor assessments and business environmental assessment. DelveInsight is a knowledge partner for business strategy and market research across the drug value chain.

Reference

201698 | DIEI0348

Number of Pages

50

Report Format

PDF

Delve Insight Reports

Related Reports

TitleDate PublishedPrice fromMore Details
SAVE 15% today! Ulcerative Colitis - Pipeline Review, H1 2017
Ulcerative Colitis - Pipeline Review, H1 2017SummaryGlobal Markets Direct's latest Pharmaceutical an...
09 May 2017 by Global Markets Direct USD $1,700 (normally
USD $2,000)
More Info
SAVE 15% today! Global Ulcerative Colitis Partnering 2010-2017
The Global Ulcerative Colitis Partnering Terms and Agreements since 2010 report provides understandi...
01 Apr 2017 by Current Partnering USD $1,271 (normally
USD $1,495)
More Info
SAVE 15% today! Global Ulcerative Colitis Partnering 2010-2017
The Global Ulcerative Colitis Partnering Terms and Agreements since 2010 report provides understandi...
01 Feb 2017 by Current Partnering USD $1,271 (normally
USD $1,495)
More Info
SAVE 15% today! Global Ulcerative Colitis Partnering 2010-2016
The Global Therapy Partnering Terms and Agreements since 2010 report provides understanding and acce...
01 Nov 2016 by Current Partnering USD $1,271 (normally
USD $1,495)
More Info
SAVE 15% today! Global Ulcerative Colitis Partnering 2010-2016
The Global Therapy Partnering Terms and Agreements since 2010 report provides understanding and acce...
01 Oct 2016 by Current Partnering USD $1,271 (normally
USD $1,495)
More Info
SAVE 15% today! Ulcerative Colitis Global Clinical Trials Review, H2, 2016
Ulcerative Colitis Global Clinical Trials Review, H2, 2016SummaryGlobalData's clinical trial report,...
28 Sep 2016 by Global Data USD $2,125 (normally
USD $2,500)
More Info
SAVE 15% today! Ulcerative Colitis: KOL Insight
Are UC biosimilars a real or perceived threat to branded drugs?Ulcerative colitis (UC) treatment is ...
01 Sep 2016 by FirstWord Pharma USD $6,715 (normally
USD $7,900)
More Info
SAVE 15% today! Ulcerative Colitis: Update Bulletin [Feb 2016]
IntroductionGain new KOL insights on the latest events happening in Ulcerative Colitis. Topics cover...
01 Feb 2016 by FirstWord Pharma USD $846 (normally
USD $995)
More Info
SAVE 15% today! Ulcerative Colitis: KOL Insight
Introductionipeline drugs are poised to reshape the way doctors treat ulcerative colitis (UC). But w...
01 Dec 2015 by FirstWord Pharma USD $6,715 (normally
USD $7,900)
More Info
SAVE 15% today! Ulcerative Colitis: KOL Insight
IntroductionThe Ulcerative Colitis (UC) treatment market is already undergoing radical change as new...
03 Dec 2014 by FirstWord Pharma USD $6,715 (normally
USD $7,900)
More Info

This report is published by Delve Insight

DelveInsight is a leading Business Consulting and Market Research Firm. We combine industry expertise with probing market insights in innovative ways to deliver enduring results to deliver critical information to leading decision makers.

We help our clients to find answers relevant to their business, facilitating decision-making; identify potential market opportunities, competitor assessments and business environmental assessment. DelveInsight is a knowledge partner for business strategy and market research across the drug value chain.

Download Free Report Summary PDF

Ulcerative Colitis (UC) -Epidemiology Forecast to 2027 | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.

We Stock...